跳至主要内容
临床试验/EUCTR2010-021333-31-DE
EUCTR2010-021333-31-DE进行中(未招募)不适用

Reduktion des Ischämie-Reperfusionsschadens durch ex-vivo Tacrolimus-Perfusion marginaler Organe vor Lebertransplantation (Tacrolimus-Organ-Perfusion TOP-Studie) - TOP-Studie

Klinikum der Universität München0 个研究点开始时间: 2011年6月14日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Donor:organ donor with at least two of the following marginality criteria (according to Eurotransplant manual Extnded Criteria Liver Conors, 09/03/2009):
  • donors age>65
  • macro vesicular steatosis >40%
  • Na> 165 mmol/l
  • intensive care and ventilation >7 days
  • cold ischemia time >13 hours GPT>105 U/l GOT >99 U/l
  • Bilirubin >3mg/dl Bilirubin (> 51 µmol/l)
  • giving of adrenaline
  • listing for a liver transplantation at one of the participating sites
  • first liver transplantation
  • age >18 years
  • signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 82
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 4

排除标准

  • at least one of the following riskfactors: active hepatitis B-or hepatitis C-infection
  • multi organ transplant
  • Extra hepatic tumor disease
  • refusal or withdrawal of the patient or their relatives
  • institutionalization based on official order or court order
  • missing or lacking knowledge of german, so that the understanding of the written patient information is not guaranteed

研究者

相似试验